Viking Therapeutics, Inc. (VKTX) Stock Analysis — Probabli.AI
AI-powered analysis for VKTX (Viking Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment.
Last price: $25.36 · Market cap: $3.0B
Viking Therapeutics (VKTX) represents one of the premier clinical-stage metabolic asset plays in modern biopharma. Currently trading near 52-week lows at $25.36 with a market capitalization of $3.0B, VKTX has suffered from retail frustration over launch timelines and earnings misses inherent to pre-revenue biotech companies. Despite near-term sentiment friction, the fundamental clinical asset…
Probabilistic 1-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 1-year price estimates — P10: $16 / P50: $42 / P90: $85
- VKTX trades at a steep discount ($25.36) relative to analyst consensus targets ($91.71 mean / $95.00 median), driven by near-term timeline friction and clinical trial burn. However, clinical Phase 3 progression for…
5-Year Outlook
- Bull 70% · Neutral 15% · Bear 15%
- 5-year price estimates — P10: $18 / P50: $110 / P90: $220
SWOT Highlights
- Strength: Differentiated dual GLP-1/GIP receptor agonist mechanism with demonstrated best-in-class weight loss velocity and tolerability in Phase 2
- Strength: Dual-track delivery platform with both subcutaneous injectable and oral tablet formulations of VK2735
- Risk: Pre-commercial stage with zero commercial product revenue and persistent quarterly net losses
- Risk: High clinical development cash burn requiring potential equity dilution to fund large Phase 3 programs
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
21 Wall Street analysts rate VKTX a STRONG BUY with a mean price target of $91.71.
Last analyzed · Model: gemini-3.8-flash. How this forecast works · Accuracy & validation.
VKTX forecast details · VKTX sentiment details
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- Viking Therapeutics, Inc. (VKTX) — saved
Viking Therapeutics (VKTX) represents one of the premier clinical-stage metabolic asset plays in modern biopharma. Currently trading near 52-week lows at $25.36 with a market capitalization of $3.0B, VKTX has suffered from retail frustratio
- Viking Therapeutics, Inc. (VKTX) — saved
Viking Therapeutics demonstrates high potential in the biopharmaceutical sector, particularly through its flagship VK2809, with strong advances in clinical trials. Analyst sentiment, significant pipeline opportunities, and projected milesto
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.